RECRUITING

COBRA: Cancer, Older Adults, Balance and Resistance Activities

Conditions

Primary Cancer Metastatic Cancer Cancer 25-090 Memorial Sloan Kettering Cancer Center

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to find out whether an 8-week digital health promotion program called COBRA is a safe and practical (feasible) option for older adults with cancer/OAC.

Official Title

COBRA: Cancer, Older Adults, Balance and Resistance Activities

Quick Facts

Study Start:2025-05-30

Study Completion:2027-05-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07011862

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy. 2. Individuals with metastatic cancer may be included provided they have stable disease or better per most recent restaging exam at time of enrollment. * Are aged 65 years and older, with no upper age limit; * ECOG PS 0-3 or Karnofsky PS greater than or equal to 40; * Can read and speak English; * Self-report access to internet connection sufficient to support videoconferencing. * Licensed clinician (MD, RN, APP) with an interest in the care of older adults with cancer.	* Have any cognitive impairment, neurologic, musculoskeletal, or other comorbid condition (as assessed by their provider) that would prevent the individual from engaging with the digital health coaching program or complete study assessments or engage in progressive intensity levels of physical activity * Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to safely engage in progressive intensity levels of physical activity (as assessed by their provider). Patients with metastatic disease and suspected interim progression since last restaging exam will be referred back to their primary oncology care team for evaluation prior to enrollment. * Have activity restrictions post-surgery at the time of enrollment

Inclusion Criteria

Exclusion Criteria

1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy.
2. Individuals with metastatic cancer may be included provided they have stable disease or better per most recent restaging exam at time of enrollment.
* Are aged 65 years and older, with no upper age limit;
* ECOG PS 0-3 or Karnofsky PS greater than or equal to 40;
* Can read and speak English;
* Self-report access to internet connection sufficient to support videoconferencing.
* Licensed clinician (MD, RN, APP) with an interest in the care of older adults with cancer.

* Have any cognitive impairment, neurologic, musculoskeletal, or other comorbid condition (as assessed by their provider) that would prevent the individual from engaging with the digital health coaching program or complete study assessments or engage in progressive intensity levels of physical activity
* Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to safely engage in progressive intensity levels of physical activity (as assessed by their provider). Patients with metastatic disease and suspected interim progression since last restaging exam will be referred back to their primary oncology care team for evaluation prior to enrollment.
* Have activity restrictions post-surgery at the time of enrollment

Contacts and Locations

Study Contact

Kristen Fessele, PhD, RN

CONTACT

646-449-1076

fesselek@mskcc.org

Grigory Syrkin, MD

CONTACT

212-639-2397

syrking@mskcc.org

Principal Investigator

Kristen Fessele, PhD, RN

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Monmouth (Consent only)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (Consent Only)

Montvale, New Jersey, 07645

United States

Memorial Sloan Kettering Suffolk-Commack (Consent Only)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (Consent only)

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (Consent Only)

Uniondale, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Kristen Fessele, PhD, RN, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-30

Study Completion Date2027-05-30

Study Record Updates

Study Start Date2025-05-30

Study Completion Date2027-05-30

Terms related to this study

Keywords Provided by Researchers

Primary Cancer
Metastatic Cancer
Cancer
25-090
Memorial Sloan Kettering Cancer Center

Additional Relevant MeSH Terms

Primary Cancer
Metastatic Cancer
Cancer